Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
33 participants
OBSERVATIONAL
2009-04-01
2010-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
NCT05159856
Vascular Complications in Children From T1D Diagnosis
NCT05790785
The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes
NCT04098549
Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes
NCT01171248
Time To Complications Occurs in Diabetes
NCT00969956
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aims of the present proposal are therefore two-fold:
1. To study in detail the progression of atherosclerosis (and micro vascular complications) in a well characterized cohort of type 1 diabetes with a long duration of the disease. This project will be a continuation of the Oslo study, a cohort started in 1982, with the last follow-up study in 1999/2000.
2. To define factors responsible for the progression of coronary heart disease (and micro vascular complications) in this cohort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetes, type 1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of type 1 diabetes at \< 30 years of age, disease duration \> 7 but \< 30 years
* C-peptide \< 0, 1 nmol/l
Exclusion Criteria
* Diastolic blood pressure \<100mmHg
* Overt nephropathy
* Proliferative retinopathy
* Pregnancy
* A history of neuropathy
* Other chronical disease
* Treatment with other drugs except insulin and oral contraceptives
40 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Aker
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kari Anne Sveen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristian F Hanssen, Professor MD
Role: PRINCIPAL_INVESTIGATOR
Oslo university hospital, Aker, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University hospital, Aker
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-08843c/21262
Identifier Type: -
Identifier Source: secondary_id
916501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.